![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171782 |
A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.
Condition | Intervention | Phase |
Hypertension |
Drug: VALSARTAN+HYDROCHLOROTHIAZIDE |
Phase IV |
MedlinePlus related topics: | High Blood Pressure |
Drug Information available for: | Valsartan Hydrochlorothiazide |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors |
Estimated Enrollment: | 74 |
Study Start Date: | February 2004 |
Ages Eligible for Study: | 18 Years to 80 Years |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Study ID Numbers: | CVAH631BCO02 |
First Received: | September 13, 2005 |
Last Updated: | June 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00171782 |
Health Authority: | Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos |
|
|
|
|
![]() |